Decibel Therapeutics (Nasdaq: DBTX) has been added to the Russell 2000 Index as part of its quarterly IPO additions, enhancing its visibility among institutional investors. The Russell indexes, which benchmark approximately $9 trillion in assets, are crucial for investment strategies. This inclusion may positively impact Decibel's stock performance by increasing interest and liquidity. The company focuses on developing gene therapies for hearing and balance disorders, addressing significant unmet medical needs.
Decibel Therapeutics (Nasdaq: DBTX) will present at the Barclays Global Healthcare Conference on March 11, 2021, at 9:10 a.m. ET, as announced by CEO Laurence Reid, Ph.D. A live webcast will be available on the Decibel Therapeutics website, with an archived replay accessible for 90 days post-event. The company focuses on innovative treatments for hearing and balance disorders, leveraging a proprietary platform to advance gene therapies. Notably, their lead program, DB-OTO, aims to address congenital hearing loss.
Decibel Therapeutics (Nasdaq: DBTX) presented significant preclinical data for its gene therapy candidate, DB-OTO, at the 44th Annual ARO Conference. This treatment aims to restore hearing in patients with otoferlin gene mutations. The research indicated successful distribution and expression in inner ear hair cells of non-human primates, with results suggesting enhanced efficacy and reduced toxicity.
Collaborating with Regeneron Pharmaceuticals, Decibel anticipates submitting necessary applications for clinical trials in 2022.
Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology, running from February 20–24, 2021. The company will present eight podium and poster presentations focusing on its gene therapy programs, DB-OTO and DB-ATO. Key presentations include DB-OTO, aimed at treating congenital hearing loss due to otoferlin deficiency, and DB-ATO, designed for balance restoration in patients with bilateral vestibulopathy. This marks a significant step in Decibel's mission to improve hearing and balance.
Decibel Therapeutics (Nasdaq: DBTX) has priced its initial public offering (IPO) at $18.00 per share, offering 7,062,000 shares. The offering aims to raise approximately $127.1 million, excluding the underwriters’ option for an additional 1,059,300 shares. Trading is set to commence on the Nasdaq Global Select Market on February 12, 2021. The offering will close around February 17, 2021, subject to closing conditions. Citigroup, SVB Leerink, BMO Capital Markets, and Barclays are the joint managers for this IPO.